U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066657) titled 'A Study of MRG007 in Patients With Advanced Solid Tumors' on June 26.
Brief Summary: This is an open-label, multi-center, phase I/II study to evaluate the safety, efficacy, and pharmacokinetics of MRG007 in patients with unresectable locally advanced and metastatic solid tumors.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Locally Advanced or Metastatic Solid Tumors
Intervention:
DRUG: MRG007
MRG007 will be administrated as specified in the protocol.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Miracogen Inc.
Disclaimer: Curated by HT Syndication....